Description

XYZAL 5 MG (1X15)

Indications

XYZAL (Levocetirizine dihydrochloride) 5 mg is an antihistamine medication primarily indicated for the relief of symptoms associated with allergic rhinitis, including sneezing, runny or itchy nose, and itchy or watery eyes. It is also indicated for the treatment of chronic idiopathic urticaria, which is characterized by the presence of hives and itching without an identifiable cause. XYZAL is suitable for adults and children aged 6 years and older.

Mechanism of Action

Levocetirizine, the active ingredient in XYZAL, is a selective antagonist of peripheral H1 receptors. By blocking these receptors, it inhibits the action of histamine, a substance in the body that is responsible for allergic symptoms. Unlike first-generation antihistamines, which can cross the blood-brain barrier and cause sedation, levocetirizine is a second-generation antihistamine that is less likely to cause drowsiness. This selectivity allows for effective symptom relief with a lower incidence of central nervous system side effects.

Pharmacological Properties

XYZAL exhibits rapid absorption following oral administration, with peak plasma concentrations typically reached within 0.9 hours. The bioavailability of levocetirizine is approximately 85% to 90%. It has a volume of distribution of about 0.4 L/kg and is primarily eliminated through renal excretion, with approximately 85% of the dose excreted unchanged in the urine. The elimination half-life of levocetirizine is approximately 8 to 9 hours, allowing for once-daily dosing.

Contraindications

XYZAL is contraindicated in patients with a known hypersensitivity to levocetirizine, cetirizine, or any of the excipients in the formulation. It is also contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) due to the risk of accumulation and increased side effects. Caution is advised in patients with a history of urinary retention, bladder neck obstruction, or epilepsy, as these conditions may be exacerbated by the medication.

Side Effects

Common side effects associated with XYZAL include drowsiness, fatigue, dry mouth, and headache. While the incidence of sedation is lower than that of first-generation antihistamines, some patients may still experience drowsiness. Serious side effects are rare but can include hypersensitivity reactions such as anaphylaxis, angioedema, and severe skin reactions. Patients should be advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of XYZAL for adults and children aged 12 years and older is 5 mg once daily, taken in the evening. For children aged 6 to 11 years, the recommended dose is 2.5 mg once daily, also taken in the evening. It is important to swallow the tablet whole with water and not to exceed the recommended dose. In patients with renal impairment, dosage adjustments may be necessary based on the severity of the condition.

Interactions

XYZAL may interact with other medications, particularly those that cause sedation or have central nervous system effects. Concurrent use with alcohol, tranquilizers, or other sedatives may enhance the sedative effects of XYZAL, leading to increased drowsiness and impaired cognitive function. Caution should also be exercised when combining XYZAL with other antihistamines or medications that may affect renal function.

Precautions

Patients should be advised to use XYZAL with caution if they have a history of renal impairment, as dosage adjustments may be necessary. Additionally, caution is warranted in patients with a history of seizures or those who are at risk for urinary retention. It is not recommended for use in pregnant or breastfeeding women unless the potential benefits outweigh the risks, and it should be used with caution in the elderly due to the potential for increased sensitivity to side effects.

Clinical Studies

Clinical studies have demonstrated the efficacy of XYZAL in reducing the symptoms of allergic rhinitis and chronic idiopathic urticaria. In a randomized, double-blind, placebo-controlled trial, patients receiving XYZAL reported significant improvements in nasal congestion, sneezing, and itching compared to those receiving placebo. Additionally, studies have shown that XYZAL is well-tolerated, with a side effect profile similar to that of other second-generation antihistamines. The overall safety and efficacy of XYZAL make it a valuable option for the management of allergic conditions.

Conclusion

XYZAL 5 MG (1X15) is an effective antihistamine for the treatment of allergic rhinitis and chronic idiopathic urticaria. Its mechanism of action, pharmacological properties, and favorable side effect profile make it a preferred choice for patients seeking relief from allergy symptoms. As with any medication, it is important for patients to follow the prescribed dosage and consult their healthcare provider with any concerns or questions regarding its use.